Medicine price: quote on request. Every case gets a written custom quote before you commit. Your total cost is quoted per case.
We give you a written timeline estimate for your case before you commit.Get my quote

Is Kebilidi available in Saudi Arabia? How families get Kebilidi (eladocagene exuparvovec-tneq)

Creator: Reserve Meds
Published: 2026-10-13

A plain answer for families in Saudi Arabia, checked against FDA, manufacturer and regulator sources.

Reviewed by the Reserve Meds clinical operations team on 13 October 2026.

Is Kebilidi available in Saudi Arabia?

Kebilidi (eladocagene exuparvovec-tneq) is an FDA-approved one-time gene therapy given into the brain for AADC deficiency. As of 13 October 2026, we found no public record that Kebilidi is registered by SFDA in Saudi Arabia. Kebilidi is given only at specialized treatment centers, so for most families in Saudi Arabia the realistic route is treatment at a qualified center abroad, after a referral from the treating specialist. If a hospital in Saudi Arabia wants to give it locally, the manufacturer must agree to supply that hospital and the Saudi Food and Drug Authority (SFDA) must approve the import. Plan in months, not weeks (our planning estimate, not a promise). Reserve Meds helps organize the referral and logistics. We do not prescribe.

Registration in Saudi Arabia: not found in public sources as of 13 October 2026. Your hospital confirms before filing.
Legal route: Treatment at a qualified center abroad, or a hospital import request if the manufacturer agrees.
Who applies: your treating specialist refers the patient to a qualified center; a hospital in Saudi Arabia applies to SFDA only if the manufacturer agrees to supply it.
Timeline: several months (not a promise).
Medicine price: quote on request. Every case gets a written custom quote before you commit.

What Kebilidi is

Kebilidi (eladocagene exuparvovec-tneq) is made by PTC Therapeutics. The US FDA approved it on 13 November 2024 for adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. It is given as a one-time infusion into a part of the brain called the putamen, given during a planned neurosurgical procedure.

The FDA decision was based on a trial that measured changes in motor milestones after 48 weeks. Because it is given by neurosurgery, the procedure itself carries surgical risks that the treating team will explain.

The same therapy was approved earlier in Europe under the name Upstaza, for a narrower group of patients, and in the UK, Israel, Brazil and Taiwan.

The legal route in Saudi Arabia

Kebilidi is given by a neurosurgical team at a specialized treatment center. It is not a medicine a family can collect or a clinic can give in an outpatient room.

For a family in Saudi Arabia, that leaves two realistic routes. First, treatment at a qualified center abroad, after your specialist refers you and the center accepts the patient. Second, a hospital in Saudi Arabia asks the manufacturer, PTC Therapeutics, whether it will supply that hospital. If the manufacturer agrees, the hospital still needs import approval from the Saudi Food and Drug Authority (SFDA). We cannot promise that a manufacturer will agree.

How a hospital import request works in Saudi Arabia, if it is ever needed:

Because Kebilidi is approved by the US FDA, a licensed Saudi hospital can ask SFDA for permission to import it for one named patient. This is often called the named-patient route.

SFDA expects the medicine to be registered with at least one reference regulator, such as the US FDA or the European Medicines Agency. The hospital signs a declaration that it takes responsibility for safe use. A licensed importer signs a declaration covering quality during transport. The patient or a legal guardian gives written consent after the treating doctor explains the benefits and risks.

A different route, SFDA's Special Access Program, is for medicines that have no reference approval anywhere, such as products still in clinical trials. It is run through SFDA's clinical trials department and usually starts with the drug's sponsor. Kebilidi does not need that route because it already has FDA approval.

Who does what

Your treating specialist decides whether Kebilidi is right for the patient and writes the letter and prescription.
The hospital refers the patient, or files a local import request if that becomes possible.
The Saudi Food and Drug Authority (SFDA) decides whether to approve an import of an unregistered medicine.
PTC Therapeutics makes Kebilidi and decides where it can be supplied.
Reserve Meds can help organize records and logistics, and keeps your family updated. We do not give medical advice.

Documents you will usually need

A referral letter from the treating specialist: diagnosis, test results and why this treatment is being considered
Genetic or laboratory reports that confirm the diagnosis, translated into English where needed
Recent clinic notes, imaging and a list of past treatments
Passport and travel documents, if treatment happens abroad
A funding plan: personal funds, insurer approval, or a government treatment-abroad decision

Timeline, step by step

Referral. Your specialist prepares a referral letter and the medical records.
Center review. A qualified treatment center reviews the records and decides whether the patient is eligible.
Funding and travel. The family confirms funding and plans travel and accommodation.
Preparation. The center runs tests and, for some products, collects cells or tissue to make the treatment.
Treatment and follow-up. The patient is treated and then followed up by the center and the home specialist.

The overall time is our planning estimate, not a promise. The regulator and the manufacturer set their own timelines.

What Kebilidi costs

Medicine price: quote on request. Your total cost depends on the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. We do not prescribe, and we do not decide what the regulator approves.

Ask about Kebilidi in Saudi Arabia

Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.

Frequently asked questions

Is Kebilidi approved in Saudi Arabia?

As of 13 October 2026, we found no public record that Kebilidi is registered by SFDA in Saudi Arabia. The same therapy was approved earlier in Europe under the name Upstaza, for a narrower group of patients, and in the UK, Israel, Brazil and Taiwan. We did not find it in the SFDA public drugs list when we checked on 17 October 2026, so ask your hospital pharmacy to confirm the status in SFDA's system before anything is filed.

Who applies for permission to use Kebilidi in Saudi Arabia?

For treatment abroad, your specialist refers the patient to a qualified center. For a local hospital import, the hospital applies to the Saudi Food and Drug Authority (SFDA), and the manufacturer must agree to supply.

How long does it take to get Kebilidi in Saudi Arabia?

Plan in months, not weeks. The center must review the records, accept the patient and prepare the treatment. This is our planning estimate, not a promise.

How much does Kebilidi cost?

Medicine price: quote on request. Your total cost, including shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Can Kebilidi be given in Saudi Arabia instead of abroad?

Only if the manufacturer agrees to supply a hospital in Saudi Arabia and SFDA approves the import. We will tell you honestly if that is not possible today.

Sources

Checked on 13 October 2026. Regulator rules change. Your hospital pharmacy confirms the current procedure before filing.